FY2026 First Quarter Results Briefing Session Material
Filed with TSE · · 27 pages · English and French
Disclaimer Regarding Forward-Looking Statement • This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Company’s financial results and other data. Such forward-looking statements are based on the Company’s assumptions, estimates, outlook, and other judgments made in light of information available at the time of disclosure of such statements
JCR Pharmaceuticals Co., Ltd. on 6ix
In the deck
Earlier from JCR Pharmaceuticals
- JCR Pharmaceuticals - Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation
- JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
- JCR Pharmaceuticals Announces Development Plan in Japan for Givinostat for Duchenne Muscular Dystrophy
- Matters Concerning Controlling Shareholders (Affiliated Companies)
- JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
Later from JCR Pharmaceuticals
- JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy
- Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for JR-141 in the United States, Europe, and Latin America
- Consolidated Financial Results for the Six Months ended September 30, 2026 (FY2026) (Japanese standard)
- FY2026 Second Quarter Results Briefing Session Material
Follow JCR Pharmaceuticals into a list and get an email when it puts out news.
Follow JCR Pharmaceuticals